Brief: Reata Pharmaceuticals Inc Submits NDA For Co’s Program Bardoxolone In Alport Syndrome
01/03/2021 13:44
March 1 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. SUBMITS NDA FOR COMPANY’S LEAD
PROGRAM: BARDOXOLONE IN ALPORT SYNDROME
Source text for Eikon: ID:nGNX1RSK1J
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer